ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
Name:
mdz394.027.pdf
Size:
101.3Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract
Authors
Abou-Alfa, GKMercade, TM
Javle, M
Kelley, RK
Lubner, S
Adeva, J
Cleary, JM
Catenacci, DV
Borad, MJ
Bridgewater, JA
Harris, WP
Murphy, AG
Oh, DY
Whisenant, J
Wu, B
Jiang, L
Gliser, C
Pandya, SS
Valle, Juan W
Zhu, AX
Affiliation
Medicine, Memorial Sloan-Kettering Cancer Center, New York, NYIssue Date
2019
Metadata
Show full item recordCitation
Abou-Alfa GK, Macarulla Mercade T, Javle M, Kelley RK, Lubner S, Adeva J, et al. LBA10_PRClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Annals of Oncology. 2019;30(Supplement_5):872.Journal
Annals of OncologyDOI
10.1093/annonc/mdz394.027Additional Links
https://dx.doi.org/10.1093/annonc/mdz394.027Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz394.027